Strategic acquisition Following the acquisition by Astoriom in January 2026, there is an opportunity to engage the enlarged global stability storage portfolio for cross-sell of additional cGMP storage services and biorepository capabilities across Astoriom’s network.

Multi-region footprint With four fully validated cGMP facilities across North America (Wilson NC, Hopedale MA, Fort Lauderdale FL, El Segundo CA) and long standing storage capabilities, position complementary services to pharma and biotech firms seeking regional stability storage near their clinical and commercial hubs.

Compliance and security 24/7 monitored systems, 21 CFR Part 11 compliant monitoring, restricted access and backup power reassure risk-averse customers; leverage these controls in target pitches to consider them for high-value or regulated samples requiring audit trails and fortified security.

Flexible storage options A broad range of conditions from ambient to ultra-low temperatures including LN2, 2-8C and -80C enables the company to support diverse stability studies, biospecimen preservation, and accelerated aging programs for clients in pharma, biotech, and biopharma contract research.

Engagement signals Active industry presence as a Gold sponsor of ECU Spring Pharma Conference and recent market expansion history indicate readiness for channel partnerships, pilot programs, and co-marketing with CROs, CRO networks, and university-industry consortia to accelerate client acquisition.